Drug Profile

Pepinemab - Vaccinex

Alternative Names: moAb VX15/2503; VX 15; VX 15/2503

Latest Information Update: 28 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaccinex
Developer Bristol-Myers Squibb; Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; UCLAs Jonsson Comprehensive Cancer Center; Vaccinex
Class Antibodies; Antidementias; Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action CD100 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Huntington's disease
New Molecular Entity Yes
Available For Licensing Yes - Alzheimer's disease; Huntington's disease

Phase II Huntington's disease
Phase I/II Adenocarcinoma; Alzheimer's disease; Non-small cell lung cancer; Osteosarcoma; Solid tumours; Squamous cell cancer
No development reported Colorectal cancer; HER2 positive breast cancer; Malignant melanoma; Multiple sclerosis; Pancreatic cancer

28 Jul 2026 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
18 Jun 2026 Vaccinex suspends phase I trials in Her2 positive Breast cancer (Second-line therapy or greater, Combination therapy, Metastatic disease) in USA, stating that the company is waiting for the DLT period with current patient and will not be enrolling any more (IV) (NCT05378464)
28 Apr 2026 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com